HPCI News: Lower Prescription Drug Prices

To: Members and Selected Others

Health and Human Services Secretary Azar recently announced actions to execute on his plan to lower prescription drug prices. The three key initiatives below hold real promise to add value and reduce cost.

FDA Announces a Biosimilar Action Plan
The FDA released a Biosimilar Action Plan outlining how to improve efficiency and scientific and regulatory clarity for product development, increase communications to expand use of biosimilar and support market competition by reducing gaming

FDA Actions to Improve Access to Over-the-Counter Drugs
The FDA released draft guidance on two innovative approaches to increase access to a broader selection of nonprescription drug products for consumers, empowering them to self-treat common conditions and potentially some chronic conditions.

Prescription Drug Importation Workgroup Established
Requested that FDA Commissioner Scott Gottlieb establish a working group to examine how to safely import prescription drugs from other countries in the event of a dramatic price increase for a drug produced by one manufacturer and not protected by patents or exclusivities.

For more information please contact the HPCI office.



Paul M. Pietzsch, MPH
HPCI - IHBA Office
4430 Ashley Park Drive
West Des Moines, Iowa 50265
(515) 778-6300

back to the top